Sugi Predict

Sugi Predict / Compounds / SCHEMBL2932824

SCHEMBL2932824

SCHEMBL2932824

NC(=O)c1cnccc1CN1C(=O)N(c2ccc(OC(F)(F)F)cc2)C(=O)C12CC2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GCGR P47871 4/20 0.45
▸ ROCK2 O75116 1/20 0.38
▸ MCHR1 Q99705 7/20 0.36
▸ CYP3A4 P08684 4/20 0.36
▸ KDM5A P29375 1/20 0.35
▸ KDM4C Q9H3R0 1/20 0.35
▸ KDM5B Q9UGL1 1/20 0.35
▸ IGF1R P08069 2/20 0.35
▸ MMP1 P03956 1/20 0.34
▸ MMP3 P08254 1/20 0.34
▸ MMP9 P14780 1/20 0.34
▸ MMP8 P22894 1/20 0.34
▸ MMP13 P45452 1/20 0.34
▸ MMP14 P50281 1/20 0.34
▸ SYK P43405 1/20 0.34
▸ TRPV1 Q8NER1 1/20 0.34
▸ TEAD1 P28347 1/20 0.34
▸ TEAD4 Q15561 1/20 0.34
▸ TEAD2 Q15562 1/20 0.34
▸ TEAD3 Q99594 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2940221 0.92 GCGR (0.43) GCGRROCK2MCHR1CYP3A4IGF1R
SCHEMBL2942195 0.92 GCGR (0.47) GCGRMCHR1CYP3A4KDM5AKDM4C
SCHEMBL3723623 0.89 GCGR (0.46) GCGRMCHR1CYP3A4IGF1R
SCHEMBL2932166 0.89 GCGR (0.48) GCGRROCK2MCHR1CYP3A4IGF1R
SCHEMBL2940023 0.89 GCGR (0.45) GCGRMCHR1CYP3A4IGF1R
SCHEMBL2988142 0.89 GCGR (0.45) GCGRMCHR1CYP3A4IGF1R
SCHEMBL3728105 0.88 IGF1R (0.47) IGF1R
SCHEMBL2939895 0.88 GCGR (0.44) GCGRMCHR1CYP3A4KDM5AKDM4C
SCHEMBL2941101 0.88 GCGR (0.46) GCGRMCHR1CYP3A4KDM5AKDM4C
SCHEMBL2940530 0.87 GCGR (0.42) GCGRMCHR1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825115-B2 Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2010-11-02 — — US disclosed
EP-1599464-B1 NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS AVENTIS PHARMA SA (FR) 2010-09-22 — — EP disclosed
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors AVENTIS PHARMA S.A. (FR) 2008-05-08 — — US disclosed
US-7354933-B2 Protein kinase inhibitors; antitumor agents; such as 5-methyl-1-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate AVENTIS PHARMA SA (FR) 2008-04-08 — — US disclosed
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2004-12-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors PRKG1, PRKACA, CMPK1 GCGR 2462/4885ROCK2 1112/4885MCHR1 4505/4885
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors PRKG1, PRKACA, PRKCA GCGR 2407/4885ROCK2 894/4885MCHR1 4236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.